XNAS · NMRA
+0.63% · +$0.0100 · Vol 656.0K
After hours · updated 16:01:35 ET
Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$1.61
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
NMRA
Neumora Therapeutics, Inc. Common Stock
Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET
SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

38/ 100
Veridion Score
SELL BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is NMRA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading NMRA catalysts
About Neumora Therapeutics, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2023
Employees
92
Country
US

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.58
Day high
$1.66
Day low
$1.54
Previous close
$1.60
52W high
$3.59
-55.15% from high
52W low
$0.9145
26% of range
Market cap
$296.5M
EPS
$-1.4000
Beta
-0.52
Shares out
185.3M
Volume
656K
0.47× rel vol
Avg volume
1.4M
VWAP
$1.60
Price history computed in-house
1W
-2.42%
1M
-4.73%
3M
-17.01%
1Y
-3.01%
YTD
-10.06%
SMA 50 $1.64 · below
SMA 200 $2.17 · below
52W position 26%

NMRA overview

Veridion Score
38
4 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around NMRA.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading NMRA Form 4 filings
Public disclosures

Congress activity in NMRA

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for NMRA in the cached public ledger.

Federal contracts

NMRA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NMRA in this window.
Lobbying spend

NMRA lobbying filings, year to date.

Registered lobbying filings matched to Neumora Therapeutics, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NMRA in this window.
Loading news for NMRA
Analyst ratings
Sovereign unlock shows live analyst consensus for NMRA.
Options
Sovereign unlock shows live options positioning for NMRA.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.